Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2LZIY)

• Drug Name: BT-061 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Phase 2	[1]
Psoriasis vulgaris	EA90	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DM2LZIY

Molecule-Related Drug Atlas

Drug(s) Targeting T-cell surface glycoprotein CD4 (CD4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibalizumab	DMV67QO	Human immunodeficiency virus infection	1C62	Approved	[3]
TNX-355	DMYA41S	Human immunodeficiency virus infection	1C62	Phase 3	[4]
Zanolimumab	DMKB4ZY	Lymphoma	2A80-2A86	Phase 3	[5]
Magrolimab	DMVXUR0	Acute myeloid leukaemia	2A60	Phase 3	[6]
Fluoropeptide vaccine	DMCEUOH	Influenza virus infection	1E30-1E32	Phase 2	[7]
LIPO-4	DMJRALD	Human immunodeficiency virus infection	1C62	Phase 1	[8]
Combinectin	DMTLP1N	Human immunodeficiency virus infection	1C62	Phase 1	[9]
TMB-365	DMH3E5C	Human immunodeficiency virus-1 infection	1C62	Phase 1	[10]
CD4CAR	DM09SW6	T-cell leukaemia	2A90	Phase 1	[11]
VRC07-523LS	DM0S9OT	Human immunodeficiency virus-1 infection	1C62	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
T-cell surface glycoprotein CD4 (CD4)	TTN2JFW	CD4_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT01072383) Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis. U.S. National Institutes of Health.
• [2] Tregalizumab (BT-061) increases regulatory T cell function. Boosting regulatory T-cell function with the humanized CD4-specific humanized monoclonal antibody Tregalizumab (BT-061). Immunol Cell Biol.2015 Apr;93(4):321-2.
• [3] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [4] Progress in targeting HIV-1 entry. Drug Discov Today. 2005 Aug 15;10(16):1085-94.
• [5] Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007 Jun 1;109(11):4655-62.
• [6] Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021 Jul;48:100791.
• [7] A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety. Vaccine. 2015 Jan 3;33(2):396-402.
• [8] Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine. 2013 Sep 13;31(40):4406-15.
• [9] Clinical pipeline report, company report or official report of ViiV Healthcare.
• [10] Clinical pipeline report, company report or official report of TaiMed Biologics.
• [11] Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
• [12] Clinical pipeline report, company report or official report of TaiMed Biologics.